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Radical radiotherapy is a standard form of management of localised prostate cancer. Conformal treatment planning spares adjacent
normal tissues reducing treatment-related side effects and may permit safe dose escalation. We have tested the effects on tumour
control and side effects of escalating radiotherapy dose and investigated the appropriate target volume margin. After an initial 3–6
month period of androgen suppression, 126 men were randomised and treated with radiotherapy using a 2 by 2 factorial trial design.
The initial radiotherapy tumour target volume included the prostate and base of seminal vesicles (SV) or complete SV depending on
SV involvement risk. Treatments were randomised to deliver a dose of 64Gy with either a 1.0 or 1.5cm margin around the tumour
volume (1.0 and 1.5cm margin groups) and also to treat either with or without a 10Gy boost to the prostate alone with no
additional margin (64 and 74Gy groups). Tumour control was monitored by prostate-specific antigen (PSA) testing and clinical
examination with additional tests as appropriate. Acute and late side effects of treatment were measured using the Radiation
Treatment and Oncology Groups (RTOG) and LENT SOM systems. The results showed that freedom from PSA failure was higher in
the 74Gy group compared to the 64Gy group, but this did not reach conventional levels of statistical significance with 5-year
actuarial control rates of 71% (95% CI 58–81%) in the 74Gy group vs 59% (95% CI 45–70%) in the 64Gy group. There were 23
failures in the 74Gy group and 33 in the 64Gy group (Hazard ratio 0.64, 95% CI 0.38–1.10, P¼0.10). No difference in disease
control was seen between the 1.0 and 1.5cm margin groups (5-year actuarial control rates 67%, 95% CI 53–77% vs 63%, 95% CI
50–74%) with 28 events in each group (Hazard ratio 0.97, 95% CI 0.50–1.86, P¼0.94). Acute side effects were generally mild and
18 weeks after treatment, only four and five of the 126 men had persistent XGrade 1 bowel or bladder side effects, respectively.
Statistically significant increases in acute bladder side effects were seen after treatment in the men receiving 74Gy (P¼0.006), and
increases in both acute bowel side effects during treatment (P¼0.05) and acute bladder sequelae (P¼0.002) were recorded for
men in the 1.5cm margin group. While statistically significant, these differences were of short duration and of doubtful clinical
importance. Late bowel side effects (RTOGX2) were seen more commonly in the 74Gy and 1.5cm margin groups (P¼0.02 and
P¼0.05, respectively) in the first 2 years after randomisation. Similar results were found using the LENT SOM assessments. No
significant differences in late bladder side effects were seen between the randomised groups using the RTOG scoring system. Using
the LENT SOM instrument, a higher proportion of men treated in the 74Gy group had Grade X3 urinary frequency at 6 and 12
months. Compared to baseline scores, bladder symptoms improved after 6 months or more follow-up in all groups. Sexual function
deteriorated after treatment with the number of men reporting some sexual dysfunction (GradeX1) increasing from 38% at baseline
to 66% at 6 months and 1 year and 81% by year 5. However, no consistent differences were seen between the randomised groups.
In conclusion, dose escalation from 64 to 74Gy using conformal radiotherapy may improve long-term PSA control, but a treatment
margin of 1.5cm is unnecessary and is associated with increased acute bowel and bladder reactions and more late rectal side effects.
Data from this randomised pilot study informed the Data Monitoring Committee of the Medical Research Council RT 01 Trial and
the two studies will be combined in subsequent meta-analysis.
British Journal of Cancer (2005) 92, 488–498. doi:10.1038/sj.bjc.6602301 www.bjcancer.com
Published online 1 February 2005
& 2005 Cancer Research UK
Keywords: prostate cancer; phase III trial; conformal radiotherapy; dose escalation; radiation toxicity; PSA
                                                                                      
Radiotherapy is one of the curative treatment options for localised
prostate cancer (Consensus conference, 1987; COIN Guidelines,
1999). Considerable advances in radiation technology over the last
decade have led to the development of conformal radiation
treatments, which more closely match the high dose volume to the
tumour target while reducing the radiation to dose-limiting normal
tissues (Fuks and Horwich, 1993). The potential advantage of these
techniques is to enable a reduction in radiation-related side effects
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sas well as permitting the safe delivery of high doses of radiation,
which might improve treatment efficacy. Institutional experiences
and results from phase I/II studies suggest that both these goals
may be achievable (Sandler et al, 1992; Hanks et al, 1998; Zelefsky
et al, 1998) and that dose/response relationships exist for tumour
control as well as dose/volume/complication relationships for the
development of late normal tissue damage. However, only two
phase III randomised trials using photon beam treatment have
been reported. In the first, we compared conventional and
conformal radiotherapy (CFRT) at a standard dose of 64Gy
(Dearnaley et al, 1999) and showed a significant reduction in the
dose-limiting late side effect of proctitis using CFRT. In the second
trial, conventional radiotherapy (70Gy) was compared with a
mixed schedule of conventional and CFRT to a dose of 78Gy. In
this study, an improvement in failure-free survival with higher
dose was suggested but radiation proctitis was also increased
(Pollack et al, 2000).
An alternative strategy to improve the local treatment results of
radiation therapy is to use an initial period of androgen suppression/
blockade. Potential advantages of combined modality treatment
include an additive or synergistic effect on tumour cell kill and also a
reduction in radiation target volume (Dearnaley, 2001). Four phase
III randomised trials have reported benefits in tumour control
compared to radiation alone (Laverdiere et al, 1997, 2004; Porter et al,
1998; Pilepich et al, 2001), and an overview of the Radiation
Treatment and Oncology Groups (RTOG), experience suggested an
overall improvement in survival using neoadjuvant androgen
suppression in addition to radiotherapy (Roach III et al, 2000).
Several groups have measured the reduction in prostate and prostate
target volume after initial hormone treatment, which varied between
2 5a n d4 1 %a n ds h o w e dac o m p l i m e n t a r yi n c r e a s ei nt h es p a r i n go f
rectum and bladder when initial hormone treatment was combined
with CFRT (Zelefsky et al, 1994; Forman et al, 1995; Dearnaley, 2000).
However, there is currently no evidence to suggest whether or not the
i n i t i a lo rp o s t h o r m o n et r e a t m e n tp r o s t a t ev o l u m es h o u l db eu s e dt o
construct the radiation target volume. This issue is complicated by
the need to define a ‘safety margin’ around target tissues to account
for the day to day variations in patient and prostate position and the
accuracy of radiation delivery (Tinger et al, 1998; Wu et al, 2001).
In our study we wanted to evaluate the role of dose escalation
using conformal radiotherapy in conjunction with initial androgen
suppression. We constructed a phase III randomised trial using a
2 2 factorial design to assess, firstly, our standard dose of 64Gy
compared to the escalated dose of 74Gy and, secondly, to compare a
radiation ‘safety margin’ of 1.0cm to that of 1.5cm. The trial was
initially designed as a single institution study at the Royal Marsden
NHS Trust (RMT) and Institute of Cancer Research (ICR), but the
opportunity came to develop the protocol further with the then
newly formed Medical Research Council (MRC) Radiotherapy
Working Party. A national multicentre trial (MRC RT01) com-
menced in January 1998 (Seddon et al, 2000; Sydes et al,2 0 0 4 )a t
which time recruitment to our single institutional trial stopped. We
had previously agreed with the MRC RT01 trial coordinating
committee that the single institution trial would act as a ‘pilot
study’ for the national trial, all data being sent to the MRC Data
Monitoring Committee, and that in due course the trials would be
reported separately before being combined in meta-analysis. Dose-
limiting late side effects of radiation treatment may take 2 years or
more to develop after therapy, and this pilot study allowed the
national study to proceed with an additional degree of safety.
PATIENTS AND METHODS
Eligibility
The study was approved by the RMT and ICR Clinical Research
and Ethics Committees. All men participating in the trial gave
written informed consent. Patients with histologically proven T1b-
T3b N0 M0 (UICC, 1997) adenocarcinoma of the prostate were
eligible provided there was no past or current medical history,
which made radical radiotherapy inappropriate, and there had
been no previous androgen suppression or pelvic radiotherapy.
Patients were not excluded on the basis of pretreatment prostate-
specific antigen (PSA) levels alone and there was no specified
upper age limit to trial entry.
Pretreatment investigations
All men were assessed by clinical history and physical examination
including digital rectal examination (DRE). Full blood count and
biochemistry including creatinine, alkaline phosphatase and PSA
levels were measured. Prostate-specific antigen samples were taken
at least 10 days after any biopsy procedure and before rectal
examination. Histopathology was reviewed at the RMT, using
either Gleason or WHO reporting systems (Murphy et al, 1994).
Staging of the primary disease was by DRE, supplemented by
transrectal ultrasound (TRUS) and magnetic resonance imaging
(MRI). Clinical staging was used to assign risk-group categories
unless there was considered to be unequivocal evidence of
upstaging on MRI. All patients had lymph node assessment using
computer tomography (CT) or MRI. All patients had a bone scan
with any appropriate correlative X-rays.
TREATMENT
Neoadjuvant androgen suppression
Androgen suppression was achieved using monthly depot injec-
tions of a luteinising hormone-releasing hormone analogue
(LHRHa) using cyproterone acetate (CPA) 100mg three times
daily to prevent testosterone ‘flare’. Cyproteronone acetate was
commenced 1 week prior to the first LHRHa and discontinued
after a further 2 weeks. Luteinising hormone-releasing hormone
analogue treatment was given for 3–6 months before radiotherapy
with testosterone suppression continuing until the end of radio-
therapy, after which all treatment was discontinued.
Radiotherapy treatment
Radiotherapy treatment was designed on planning CT scans using
a slice interval of 5mm, which were performed approximately 12
weeks after commencement of hormone therapy. Patients were
treated supine, with a comfortably full bladder. No contrast agents
were given. Positioning was achieved using laser alignment of
anterior and lateral tattoos sited in the plane of the superior border
of the symphysis pubis. Ankle stops were used to aid immobilisa-
tion (Nutting et al, 2000). Outlining of target and normal tissues
(rectum, bladder, femoral heads) was carried out on contiguous
CT slices; the rectum and bladder were outlined as ‘solid’
organs using IGE Target or Cadplan systems. The bladder was
contoured from apex to dome and rectum from the anus (at
the level of the ischial tuberosities) for 14cm or to the point at
which the rectosigmoid junction was identified. Volumes of
target tissues (prostate þ/  seminal vesicles) were defined as in
Table 1 according to ICRU Report 50 (ICRU, 1993). Patients were
stratified into low- or moderate-risk groups for seminal vesicle
involvement (Roach III, 1993). Patients with a risk of seminal
vesicle involvement of o15% had the gross tumour volume
defined as prostate and base of seminal vesicles alone; those
patients with a higher risk of involvement had the seminal vesicles
included in the phase I gross tumour volume (GTV1). All patients
randomised to receive 74Gy had a boost to the prostate only
(GTV2). Patients were additionally randomised to have either a 0.5
or 1.0cm margin added to the GTV1 to create the clinical
target volume (CTV1). A further 0.5cm was added to form the
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splanning target volume (PTV1). The phase II boost treatments
were given to the prostate only with no added margin
(GTV2¼CTV2¼PTV2). The rationale for the randomisation
between a 0.5 and 1.0cm margin between the GTV1 and CTV1
was based on our previous experience using neoadjuvant androgen
suppression (Dearnaley, 2000). We observed an approximate 50%
reduction in prostate volume from a mean of 84 to 47cm
3.
Assuming a spherical shape, this corresponds to a change in radius
of 0.5cm (2.7cm reducing to 2.2cm). All patients received initial
treatment to PTV1 to a dose of 64Gy in 2Gy fractions treating
daily over a period of 6 1/2 weeks. Patients randomised to the
escalated dose arm received an extra five fractions of 2Gy given
over 1 week to the PTV2. Doses were defined at the isocentre. A
three-field plan (anterior and left/right lateral or posterior oblique
fields) was used for phase I plan (Khoo et al, 2000) with a six-field
arrangement (left and right, anterior/posterior oblique and lateral
fields) for phase 2 (Pickett et al, 1994). Treatments were delivered
using 6–10MV photons and fields shaped using multileaf
collimators (MLC) or customized, shaped blocks. Orthogonal
simulator films were taken to verify the orientation and align-
ment of the planned fields. Port films/images were taken initially
on a daily basis and subsequently on a weekly basis to verify
treatment accuracy.
Patient follow-up
Acute bowel and urinary side effects were assessed weekly during
therapy (weeks 1–6) and week 8, 10 and 18 using the RTOG system
(Cox et al, 1995). Late radiation side effects were assessed using
RTOG criteria (Lawton et al, 1991) and also the RTOG/EORTC
LENT SOM (1995) (Late Effects Normal Tissue – Subjective
Objective Management) classification at 6, 12, 18 and 24 months
after treatment and thereafter annually. The RTOG system gives a
consolidated score of all bladder or bowel symptoms on a six-point
scale. The majority of patients will develop any signs of late
morbidity within the first 2 years of treatment. The LENT SOM
questionnaire comprises 13 questions on rectal function, 14 on
bladder function, seven on sexual dysfunction and data were also
collected on potential small intestine/colon, skin/subcutaneous
tissue and bone side effects. Each question is answered on a five-
point scale. The highest score from each set of questions has been
reported when summarising results. Assessment of disease status
was made using PSA measurements, clinical assessment and DRE
at 6 weekly intervals during hormone therapy, then at 3, 6, 12, 18
and 24 months and then at annual intervals. Prostate-specific
antigen was measured using the Hybritech enzyme immunoassay
and the Roche immunometric assay prior to 1997. These assays
provided results to the nearest ngml
 1 with a lower limited
detection of 1ngml
 1. In January 1997, the Abbot AXSYM assay
was adopted with a lower limit of 0.1ngml
 1. Given the limitations
of the assays used during the earlier years of the study, we defined
biochemical failure as either two consecutive rises in PSA
X2ngml
 1, or the recommencement of androgen deprivation.
The date of PSA failure was taken as the date of the first PSA value
X2ngml
 1, or the date of starting androgen deprivation,
respectively.
Trial design, end points and statistics
The trial was designed as a prospective randomised phase III study
using a 2 2 factorial design to study dose escalation and
treatment volume. Patients’ radiotherapy treatments were rando-
mised between (a) total dose of 74 vs 64Gy; (b) treatment margin
(GTV-PTV) of 1.0 vs 1.5cm.
Comparisons have been made between the randomised
groups only. Independent randomisation was undertaken by
ICR Clinical Trials and Statistics Unit using a randomised
permuted block design. Stratification of patients was according
to calculated risks of seminal vesicle involvement (Roach III,
1993). In a trial of this type, it was impractical to use any ‘blinding’
procedures.
Statistical considerations and analysis
The primary end points were a comparison of disease control and
treatment-related side effects. The trial was originally designed to
have 80% power to detect an improvement in biochemical (PSA)
control of 14% (50% increasing to 64%) and in local tumour
control of 10% (80% increasing to 90%) 5 years after treatment
(a¼0.05, one sided). It was calculated that 314 men would be
required. Similar numbers were needed to exclude a 10% (15%
rising to 25%) increase in Grade 2 (clinically relevant) late side
effects (a¼0.05, one sided). Allowing for 10% of the study
population to be unevaluable, 350 men were required for trial
completion. However, as described above, recruitment was
stopped after 127 men had been randomised in favour of the
national protocol. Results presented here therefore are primarily
hypothesis generating.
The treatments were evaluated in terms of biochemical control
(PSA failure) and acute and late toxicities. Time to PSA failure was
calculated from the date of randomisation with patients censored
at the date of the last follow-up or death. Cumulative survival
curves were constructed as time to event plots by the Kaplan–
Meier method. Differences between the curves were tested for
significance using the logrank test. Cox regression models were
used to calculate treatment effects on time to PSA failure; these are
presented as hazard ratios (HR) with their 95% confidence limits.
Prostate-specific antigen nadir levels were compared using
the Mann–Whitney U-test. Differences in acute toxicities and
late toxicities reported using the RTOG criteria were analysed
using the w
2 test for trend using groups based on grade
0/1/2þ and 0/1/2/3þ, respectively. Differences in late radiation
effects reported using the LENT SOM questionnaire were analysed
using the w
2 test (no symptoms vs any symptoms). Although
the use of one-sided tests may be appropriate as increases in
both dose and treatment volume could only be associated
with higher rates of disease control and complications, to avoid
any chance of misrepresenting our findings two-sided significance
Table 1 Definition of radiation target volume
Radiation dose Risk group
a Gross tumour volume (GTV) Clinical target volume (CTV) Planning target volume (PTV)
Phase I
64 and 74Gy groups Low-risk SV involvement
b Prostate+base SV GTV1+0.5 or 1.0cm
c CTV1+0.5cm
Moderate-risk SV involvement
d Prostate+SV GTV1+0.5 or 1.0cm
c CTV1+0.5cm
Phase II
74Gy group All cancers Prostate only GTV2 (no added margin) CTV2 (no added margin)
aRisk of seminal vesicles (SV) involvement (%)¼prostate-specific antigen (PSA) +(Gleason score 6 10) for T1/T2 cancers (Roach III, 1993).
bT1/T2 cancers with SV
involvement risk o15%.
cRandomised treatment options.
dT3/T4 cancers and T1/T2 cancers with SV involvement risk X15%.
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slevels are reported throughout. Statistical analyses were performed
using SPSS (version 11.5.1) and STATA (version 7.0) software
packages.
RESULTS
Between July 1995 and December 1997, 127 men were randomised.
One patient withdrew before any treatment was given and is
excluded from this analysis (Figure 1). All other men received their
allocated treatments. The median age of patients was 67 years
(interquartile range (IQR) 62–72 years). The median presenting
PSA level was 14ngml
 1 (range 1–142ngml
 1). Of the 126 men,
21% had T1b/T1c cancers, 50% T2 cancers and 29% clinical T3
cancers. Histologically 18% of cancers were well differentiated or
had Gleason Scores of 2–4, 72% were moderately differentiated
or had Gleason Scores of 5–7 and 10% were poorly differen-
tiated or had Gleason Scores of 8–10. Presenting features were in
general well balanced between the randomised groups (Table 2).
Although there were more T3 cancers in the 64Gy dose group
(P¼0.03), this was balanced by more patients with poorly
differentiated cancers in the 74Gy dose group so that the
calculated risk of seminal vesicle involvement (the stratifica-
tion parameter) was similar between the groups with overall
29% of men having a low risk and 71% a moderate risk of
seminal vesicle involvement. Phase I (unshaped) treatment
field areas were similar in the 64 and 74Gy groups, 101cm
2
(range 62–151cm
2) and 96cm
2 (range 52–146cm
2) for the
anterior fields and 98cm
2 (range 52–154cm
2) and 93cm
2 (range
53–136cm
2) for the lateral fields, respectively. As expected,
the treatment field areas were larger in the 1.5cm margin than
1.0cm margin groups; 111cm
2 (range 52–151cm
2) and 94cm
2
(range 57–114cm
2) for the anterior fields and 110cm
2 (range
69–154cm
2) and 86cm
2 (range 52–118cm
2) for the lateral
fields, respectively. The median size of the lateral boost field
(unshaped) in the 74Gy group was 31cm
2 (range 23–55cm
2). The
median follow-up of all patients is 6.2 years (range 0.6–8.2
years) and 98 out of 105 (93%) of living patients have at least 5
years follow-up.
Tumour control
Of the 126 men, 56 (44%) have developed biochemical PSA
failure. Five men have developed clinically detectable local
failure, and 15 have developed metastatic disease (bone 13, nodal
three, lung two, liver two). A total of 21 patients have died,
nine from prostate cancer and 12 from other causes. In total, 27
men have recommenced hormonal treatment for recurrent
disease. All clinically detectable failures were preceded by
biochemical failure (lead time, 10.7 months; IQR, 2.6–20.0
months). Of the 56 men with biochemical failure, 30 remain on
an observation policy without further treatment. We recom-
mended restarting hormonal therapy if there was clinical,
radiological or bone scan evidence of metastatic disease or a
rapid PSA doubling time (p6 months); additionally, some
patients preferred immediate to deferred hormonal therapy
for PSA only failure.
Comparing the randomised groups, 33 PSA failures have
occurred in the standard dose (64Gy) group compared to 23 in
the escalated dose group (74Gy) (logrank test P¼0.10:
hazard ratio (HR) 0.64, 95% CI 0.38–1.10) (Figure 2A). No
difference in outcome has been seen in the margin randomisation
comparison (28 events in each group, hazard ratio 0.97, 95%
CI 0.50–1.86 P¼0.94) (Figure 2B). The 5-year actuarial control
rates are 59% (95% CI 45–70%) and 71% (95% CI 58–81%) in the
64 and 74Gy groups and 67% (95% CI 53–77%) and 63% (95%
CI 50–74%) for the 1.0 and 1.5cm margin groups, respectively
(Table 3).
There is a suggestion that PSA nadir levels in the 6–24
months after radiotherapy are lower in the 74Gy group than
the 64Gy group with median levels of 0.3ngml
 1 (IQR
0.1–0.5ngml
 1) compared with 0.5ngml
 1 (IQR 0.2–0.8ngml
 1)
) for the 64Gy group (P¼0.003). Nadir levels for the 1.0
and 1.5cm margin groups were similar with median levels of
0.4ngml
 1 (IQR 0.1–0.7) and 0.3ngml
 1 (IQR 0.1–0.6ngml
 1)
(P¼0.45).
Of the 19 patients with local or metastatic failure, 12/7 were from
the 64/74Gy and 11/8 from the 1.0/1.5cm margin groups,
respectively. Hormonal therapy was restarted in 16/11 men from
Allocated 1.5 cm margin 
(N =63)
Allocated 1.0 cm margin 
(N =64)
Margin randomisation
(N =127)
Patients randomised 
2 × 2 factorial design (N =127)
Dose randomisation 
(N =127)
Allocated 64 Gy (N =64) Allocated 74 Gy (N =63) 
One patient excluded (withdrew 
consent before any treatment) One patient excluded (withdrew 
consent before any treatment)
Analysed (N =64) Analysed (N =62) Analysed (N =63) Analysed (N =63)
Number last seen within 
1 year/dead (N =55) 
Lost to follow-up (N =5) 
(Three moved out of area, one Alzheimer’s 
disease, one reason NK)
Number last seen within 
1 year/dead (N =58) 
Lost to follow-up (N =0)
Number last seen within 
1 year/dead (N =59) 
Lost to follow-up (N =1) 
(One moved out of area)
Number last seen within 
1 year/dead (N =54) 
Lost to follow-up (N =4) 
(Two moved out of area, one  Alzheimer’s 
disease, one reason NK)
Figure 1 Consort diagram.
Dose escalation using radiotherapy in prostate cancer
DP Dearnaley et al
491
British Journal of Cancer (2005) 92(3), 488–498 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthe 64/74Gy groups, respectively. There was no difference in the
time to restarting hormone therapy between the randomised
groups (5-year actuarial rate 15–16% for each group). Seven of the
nine prostate cancer deaths were in men treated in the 64Gy
group.
Acute side effects of treatment
Men were assessed at 10 time points (preradiotherapy to 18 weeks
postradiotherapy). In all, 1252 out of 1260 (99%) of assessments
were performed and have data available for analysis. In general,
treatment was well tolerated and 69 men (55%) and 73 men (58%)
had, at worst, bowel or bladder toxicity of Grade 1, at any time
during weeks 1–18. Overall, three patients had Grade 3 bowel
toxicity and 15 Grade X3 urinary toxicity – most commonly
frequency at hourly intervals or greater (Grade 3), with two men
requiring catheterisation for urinary obstruction (Grade 4). Table 4
shows acute RTOG toxicity scores reported during treatment
(weeks 1–6) and after treatment (weeks 8–18) by the randomised
group. The time course of the ‘ wave’ of acute reaction is shown in
Figure 3A–D. It would have been unexpected to see differences
between the 64Gy/74Gy dose groups during treatment as the
initial 32 daily treatments were identical but if ‘volume’ effects
exist for acute bowel/bladder radiation reactions, these might be
seen either during or after treatment. Concerning the dose
randomization, no significant differences were seen in bowel or
bladder reactions during radiotherapy (weeks 1–6), or for bowel
reaction after treatment. However, acute bladder toxicity was more
marked after treatment in the 74Gy group (P¼0.006): at 10 weeks,
toxicity scores were still elevated although in the 64Gy group
symptoms were beginning to settle. Side effects substantially
improved by week 18, and only four men had residual greater than
Grade 1 symptoms remaining in either group (Figure 3A). The
total duration of treatment (7.5 vs 6.5 weeks) as well as total dose
could be related to the differences observed. Concerning the
margin randomization, the 1.0cm margin group had less bowel
toxicity during radiotherapy (P¼0.05) and these differences were
most obvious during weeks 5 and 6 of treatment (Figure 3C).
Although there was no difference in the maximum toxicity after
treatment, which in general settled rapidly, less men had residual
Table 2 Patient and tumour characteristics
64Gy dose 74Gy dose 1.0cm margin 1.5cm margin Total
No. 64 62 63 63 126
Age (years): median (IQR) 66 (62–71) 69 (63–72) 66 (62–72) 68 (63–72) 67 (62–72)
PSA (ngml
 1) at baseline, median (IQR) 15 (7–28) 14 (7–29) 13 (7–31) 15 (7–26) 14 (7–29)
Clinical stage* (%)
T1 17 26 17 25 21
T2 44 56 52 48 50
T3 39 18 30 27 29
Histology (%)
Grade 1 19 18 14 22 18
Grade 2 77 68 79 65 72
Grade 3 5 15 6 13 10
Risk of seminal vesicle involvement (%)
Low 31 27 30 30 29
Moderate 69 73 70 70 71
*P¼0.03, w
2 test 64 vs 74Gy. PSA¼prostate-specific antigen; IQR¼interquartile range.
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Years since randomisation
1.0 cm
1.5 cm
HR=0.97 (95% CI 0.50 −1.860)
63
63
3/60
4/59
5/55
1/56
2/51
6/50
7/43
7/42
3/40
4/36
N Events/no. remaining at risk
3/29
0/31
3/12
5/12
Logrank test 2.65 P =0.10
74 Gy 
64 Gy
Logrank test 0.01 P =0.94
1.0 cm
1.5 cm
A
B
Figure 2 (A) Time to PSA failure: 74 vs 64Gy dose randomization; (B)
Time to PSA failure: 1.5 vs 1.0cm margin randomization.
Table 3 Time to prostate-specific antigen (PSA) failure analysis
% PSA failure free (95% CI)
Year 64Gy dose 74Gy dose 1.0cm margin 1.5cm margin
2 89 (78–95) 90 (80–95) 87 (76–93) 92 (82–97)
3 78 (65–86) 89 (77–94) 84 (72–91) 82 (70–90)
4 64 (51–75) 78 (65–87) 72 (59–82) 70 (57–80)
5 59 (45–70) 71 (58–81) 67 (53–77) 63 (50–74)
6 57 (43–68) 67 (53–78) 60 (53–77) 63 (50–74)
Bold represents 5-year results mentioned in text.
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sbowel problems (RTOG Grade X1) in the 1.0cm margin group at
week 18 (11% 1.0cm margin, 28% 1.5cm margin, P¼0.02) and
only five of the 126 men remained with Grade 41 toxicity. Bladder
toxicity was more marked both during and after treatment in the
1.5cm margin group (P¼0.002, P¼0.02, respectively) as seen in
Table 4 and Figure 3D. Again, as with the bowel reactions,
differences during treatment were seen most obviously during
weeks 5 and 6 and toxicity settled more quickly in the 1.0cm
margin group so that 92% of men were free of treatment-related
symptoms by week 18 compared to 72% in the 1.5cm margin
group (P¼0.004). However, only four out of 126 men remained
with Grade 41 side effects.
Late side effects of treatment
Late side effects were assessed using standard RTOG and LENT
SOM physician completed questionnaires. Annual RTOG assess-
ments 1–5 years after radiotherapy were available in 123, 118, 113,
102 and 92 patients and LENT SOM data for 115, 111, 94, 94 and 90
men, respectively. Table 5 shows the cumulative incidence of late
side effects at 2 years. Overall, 83/85% of men had at most Grade 1
bowel/bladder toxicities reported. After 2 years of follow-up,
RTOG grade X2 side effects were seen as follows: rectal bleeding
16, rectal discomfort three, bowel frequency three, and day time
urinary frequency 10, nocturia seven, dysuria one, haematuria one,
urinary incontinence three and urethral dilatation two. Comparing
the randomised groups (Table 5), Grade X2 bowel complications
were more common in the 74Gy and 1.5cm margin groups
(P¼0.02, and P¼0.005, respectively) and, of note, all three Grade
3 complications occurred in men treated to 74Gy and with a 1.5cm
margin. No significant differences were seen in bladder toxicity
although there is a suggestion of more Grade X2 complications in
the 74Gy and 1.5cm margin groups (P¼0.28 and P¼0.30,
respectively). Actuarial projections of the cumulative incidence of
Grade X2 bowel and bladder complications are shown in Figure
4A–D. A persisting trend for higher complication rates in the
74Gy and 1.5cm margin groups is seen.
Baseline LENT SOM assessment showed that 14 out of 88 (16%)
men had some rectal dysfunction. In 13 of the 14, there was
occasional rectal bleeding or bowel frequency 2–4 times per day.
This increased to 35–44% during years 1–5 of follow-up (Table 6),
but any Grade 3 toxicity was uncommon being recorded in 8% or
less of men on any particular follow-up visit. Of the 41 Grade 3
rectal toxicity scores reported in 32 men, 19 were due to rectal
bleeding, six ulceration, three tenesmus, two mucosal loss, two
stool frequency and one pain. The pattern of toxicity changed with
time, increased bowel frequency and tenesmus was recorded most
commonly at 6 months and 1-year follow-up. Thereafter,
approximately two-thirds of toxicity was due to rectal bleeding,
the remainder being caused by a constellation of tenesmus,
mucosal loss and sphincter disturbance. Comparison between the
treatment groups suggested an increased complication rate in the
dose escalated (74Gy) dose group, but this reached statistical
significance (P¼0.02) at the 4-year follow-up point only. However,
the 1.5cm margin group had a consistently higher complication
rate after treatment. The toxicity grade using RTOG and LENT
SOM systems cannot be exactly ‘translated’ but the results using
the two different systems appeared similar.
Using the LENT SOM classification, 42% of men had bladder
symptoms at baseline; frequency and poor urinary stream were
scored in all of these 37 men. At 6 months, only 27% of men were
symptomatic and this level remained constant during the
remainder of follow-up. Although consistently higher symptom
scores were recorded in the 1.5cm margin group, this reached
statistical significance only at 3 years (Table 6). At 6 months, there
was a statistically significant increase in urinary frequency in the
74Gy compared with 64Gy group with Grade X3 scores seen in
seven out of 39 (18%) and three out of 43 (7%) patients,
respectively (P¼0.03). This is consistent with the higher acute
toxicity seen at week 18 in the 74Gy group (Figure 2B). Overall,
urinary symptoms remained higher after 1 year in the 74Gy group
(P¼0.02), but this reduced on longer term follow-up (Table 6).
These differences were not detected using the RTOG scoring
system. At 6 months, 26 out of 37 (70%) of symptoms scored, and
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Figure 3 Acute bowel and bladder toxicities by dose and margin randomization. (A) Acute bowel toxicity (RTOG) by dose randomization; (B) Acute
bladder toxicity (RTOG) by dose randomization; (C) Acute bowel toxicity (RTOG) by margin randomization; (D) Acute bladder toxicity (RTOG) by margin
randomization.
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sat 12 months, 35 out of 61 (57%) of symptoms scored were of
Grade X2 urinary frequency (frequency at 2–3-h intervals or less),
intermittent poor stream and dysuria on the LENT SOM system
which may not have registered on the RTOG grading system.
The LENT SOM classification of sexual functioning comprises
questions related to adequacy of erectile function, dryness, desire,
satisfaction, frequency of intercourse and orgasm and manage-
ment of symptoms. At baseline, 38% of men reported some sexual
dysfunction (Grade X1), this increased to 66% at 6 months and 1
year and 81% by year 5. Some Grade X3 sexual dysfunction was
reported by 26% of men at baseline, which increased to 52% at 6
months, 61% at 1 year and thereafter remained stable being 57% at
5 years. Between 13 and 21% of men used some form of treatment
for sexual dysfunction at assessments between 2 and 5 years after
treatment. Comparing the randomised treatment groups at each
time point, no differences were seen except for erectile function
(Grade X3 63/42%, P¼0.04) and orgasm (Grade X3 59/38%,
P¼0.04) for 74/64Gy groups, respectively, 2 years after treatment.
As multiple comparisons were made, these findings must be
treated with caution.
No ureteric side effects were recorded and bone/skin symptoms
(p2% at any assessment) were similar to those at baseline.
DISCUSSION
The results of this randomised pilot study suggest that dose
escalation improves biochemical (PSA) control of disease and that
both radiation dose and technique impact on radiation-related side
effects. The actuarial 5-year failure-free estimate increased from
59% (95% CI: 45–70%) to 71% (95% CI: 58–81%), comparing the
64 and 74Gy treatment groups. These results are quite similar to
the findings of the only other reported phase III randomised trial
that was performed at the MD Anderson (Pollack et al, 2000). In
Table 4 Acute bowel and bladder toxicity (RTOG scoring): by dose and margin randomisations
64Gy dose (N¼64) 74Gy dose (N¼62) 1.0cm margin (N¼63) 1.5cm margin (N¼63) Total (N¼126)
n (%) n (%) n (%) n (%) n (%)
Weeks 1–18
Maximum bowel toxicity
0 14 (22) 10 (16) 13 (21) 11 (17) 24 (19)
1 22 (34) 23 (37) 27 (43) 18 (29) 45 (36)
2 25 (39) 29 (47) 22 (35) 32 (51) 54 (43)
3 3 (5) 0 (0) 1 (2) 2 (3) 3 (2)
4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
(P¼0.52) (P¼0.13)
Maximum bladder toxicity
0 15 (23) 8 (13) 14 (22) 9 (14) 23 (18)
1 26 (41) 24 (39) 33 (52) 17 (27) 50 (40)
2 16 (25) 22 (35) 10 (16) 28 (44) 38 (30)
3 7 (11) 6 (10) 5 (8) 8 (13) 13 (10)
4 0 (0) 2 (3) 1 (2) 1 (2) 2 (2)
(P¼0.08) (P¼0.002)
Weeks 1–6
Maximum bowel toxicity
0 17 (27) 16 (26) 20 (32) 13 (21) 33 (26)
1 22 (34) 20 (32) 23 (37) 19 (30) 42 (33)
2 24 (38) 26 (42) 20 (32) 30 (48) 50 (40)
3 1 (2) 0 (0) 0 (0) 1 (2) 1 (1)
4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
(P¼0.8) (P¼0.05)
Maximum bladder toxicity
0 18 (28) 12 (19) 20 (32) 10 (16) 30 (24)
1 26 (41) 25 (40) 29 (46) 22 (35) 51 (40)
2 13 (20) 17 (27) 8 (13) 22 (35) 30 (24)
3 7 (11) 6 (10) 5 (8) 8 (13) 13 (10)
4 0 (0) 2 (3) 1 (2) 1 (2) 2 (2)
(P¼0.19) (P¼0.002)
Weeks 8–18
Maximum bowel toxicity
0 28 (44) 17 (27) 25 (40) 20 (32) 45 (36)
1 16 (25) 23 (37) 21 (33) 18 (29) 39 (31)
2 18 (28) 22 (35) 16 (25) 24 (38) 40 (32)
3 2 (3) 0 (0) 1 (2) 1 (2) 2 (2)
4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
(P¼0.16) (P¼0.16)
Maximum bladder toxicity
0 22 (34) 9 (15) 17 (27) 14 (22) 31 (25)
1 27 (42) 28 (45) 34 (54) 21 (33) 55 (44)
2 10 (16) 19 (31) 9 (14) 20 (32) 29 (23)
3 5 (8) 4 (6) 2 (3) 7 (11) 9 (7)
4 0 (0) 2 (3) 1 (2) 1 (2) 2 (2)
(P¼0.006) (P¼0.02)
Trend tests (w
2
1) based on toxicity level grouping: 0, 1, X2.
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sthis trial, which included 305 men, the total radiotherapy dose was
randomised to either 70 or 78Gy but no initial hormone treatment
was given. The 5-year PSA control rates were 69 and 79%,
respectively (P¼0.06). This trial included patients with better
prognostic features (for example, median PSA 8ngml
 1 compared
to 14ngml
 1 in our current study) (Shipley et al, 1999; Parker et al,
2002). Subgroup analysis of the 106 men with presenting PSA
levels greater than 10ngml
 1 showed biochemical control rates of
48 and 75% (P¼0.01) for the 70 and 78Gy groups, respectively.
Improvements in PSA control rates of similar magnitude have also
been reported from phase II studies in larger groups of men
(Sandler et al, 1992; Hanks et al, 1998; Zelefsky et al, 1998; Fiveash
et al, 2000; Kupelian et al, 2000). For example, the Memorial Sloan
Kettering Group have reported outcome from 1100 men compar-
ing doses in the range of 64–70Gy and 76–86Gy (Zelefsky et al,
2001). Using clinical stage, histological grade and presenting PSA
to define prognostic groups showed 5-year actuarial PSA control
rates in 77 vs 90% (P¼0.05), 50 vs 70% (P¼0.001) and 21 vs 47%
(P¼0.002) of favourable, intermediate and unfavourable risk cases
treated to lower or higher doses, respectively. A critical issue is
whether or not PSA control will clearly relate to disease recurrence
or to overall survival. A retrospective analysis from the RTOG
suggests that dose escalation may indeed be related to improved
survival. In their study, which included 1465 men treated in four
protocols between 1975 and 1992, men with high-grade cancers
who received higher radiation doses (X66 vs o66Gy) had a 20%
lower risk of death from prostate cancer and a 27% reduction in
overall mortality. This benefit was not seen in men with well- or
moderately differentiated cancers (Valicenti et al, 2000). However,
these retrospective studies of sequentially treated cohorts of
patients may be subject to bias from ‘stage migration’, which has
occurred during the 1990s, resulting in an apparent overall
improvement in treatment outcome (D’Amico et al, 2002).
Prospective randomised trials are therefore needed and studies
that are being undertaken in the UK (MRC RT01 Trial), The
Netherlands, France and North America will recruit, in total, over
3000 men. When available, these trials should clarify the benefit of
dose escalation in men with disease in different prognostic
subgroups.
Our analysis of acute treatment-related side effects shows that,
in general, treatment was well tolerated but that short lasting
increases in bladder and bowel toxicity were seen in the 1.5cm
margin group and an increase in bladder, but not bowel, side
effects was seen shortly after completion of radiotherapy in the
Table 5 Late bladder and bowel toxicity (RTOG scoring) by dose and margin randomisations. Maximum toxicity in first 2 years
No. (%) of men with toxicity score
64Gy dose (N¼63) 74Gy dose (N¼61) 1.0cm margin (N¼62) 1.5cm margin (N¼62) All Patients (N¼124)
Bowel toxicity
Grade 0 30 (48) 20 (39) 33 (53) 17 (27) 50 (40)
1 26 (41) 27 (44) 21 (34) 32 (52) 53 (43)
2 7 (11) 11 (18) 8 (13) 10 (16) 18 (15)
3 0 3 (5) 0 3 (5) 3 (2)
40 0 0 0 0
P¼0.02 P¼0.005
Bladder toxicity
Grade 0 33 (52) 24 (39) 29 (47) 28 (45) 57 (46)
1 23 (37) 26 (43) 27 (44) 22 (35) 49 (40)
2 5 (8) 8 (13) 5 (8) 8 (13) 13 (10)
3 2 (3) 3 (5) 1 (2) 4 (6) 5 (4)
40 0 0 0 0
P¼0.17 P¼0.27
Table 6 Late radiation side effects on rectum and bladder: LENT SOM grading system
No. (%) of men with symptoms
Time of measurement No. assessed 64Gy dose 74Gy dose 1.0cm margin 1.5cm margin All patients
Any bladder symptoms Pretreatment 88 22 (45) 15 (38) 16 (35) 21 (50) 37 (42)
(Grades 1–4) 6 months 82 7 (16)* 15 (38)* 8 (19) 14 (36) 22 (27)
1 year 115 11 (19)* 22 (39)* 12 (21) 21 (36) 33 (29)
2 years 111 10 (18) 17 (30) 11 (20) 16 (29) 27 (24)
3 years 94 12 (26) 10 (21) 5 (12)**** 17 (33)**** 22 (23)
4 years 94 11 (23) 14 (30) 10 (22) 15 (31) 25 (27)
5 years 90 11 (24) 17 (38) 13 (30) 15 (33) 28 (31)
Any rectal symptoms Pretreatment 88 8 (16) 6 (15) 7 (15) 7 (17) 14 (16)
(Grades 1–4) 6 months 82 10 (23) 13 (33) 13 (30) 10 (26) 23 (28)
1 year 115 16 (28) 24 (42) 14 (25)* 26 (45)* 40 (35)
2 years 111 18 (38) 28 (50) 18 (32)** 28 (51)** 46 (40)
3 years 94 14 (30) 22 (47) 10 (23)*** 26 (51)*** 36 (38)
4 years 94 13 (27)* 23 (50)* 14 (31) 22 (45) 36 (38)
5 years 90 17 (38) 23 (51) 17 (39) 23 (50) 40 (44)
Significance levels comparing randomised groups: 64 vs 74Gy or 1.0cm margin vs 1.5cm margin. *P¼0.02; **P¼0.05; ***P¼0.005; ****P¼0.013. Pretreatment in this table
signifies before any treatment has begun, that is, before both hormones and RT.
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s74Gy group. Although such differences were measurable and
statistically significant, they were arguably of little clinical
significance as side effects settled within 3 months of treatment
completion. The incidence of late rectal toxicity varies consider-
ably in other studies, Grade 2 or more side effects being reported
in 2–32% of patients (Lee et al, 1996; Schultheiss et al, 1997;
Hanks et al, 1998; Zelefsky et al, 1999, 2001; Bey et al, 2000;
Michalski et al, 2000; Skwarchuk et al, 2000). Risk factors include
dose, technique, past history of diabetes mellitus, rectal volume
and the occurrence of acute toxicity (Schultheiss et al, 1997;
Denham et al, 1999; Skwarchuk et al, 2000). In this study, late side
effects following radiotherapy were in line with our previous
experience (Dearnaley et al, 1999), and 2 years after therapy, 17%
of men had experienced Grade 2 or more bowel toxicity and 15%
Grade 2 or more bladder side effects. At 2 years after radiotherapy,
there was a statistically significant increase in bowel toxicity for
both the 74Gy and 1.5cm margin groups. Although an excess of
bladder side effects was seen at this time point, they did not reach
statistical significance; however, on further follow-up, the differ-
ences in bladder toxicity became more obvious and statistically
significant for the margin randomisation. In general, the LENT
SOM assessments gave similar findings to the RTOG assessments
as reported by other groups (Anacak et al, 2001), although the
LENT SOM assessment was more sensitive at picking up minor
degrees of bladder impairment, which were seen in both the 74Gy
and 1.5cm margin groups. It is noteworthy that after treatment,
the degree of bladder dysfunction was decreased from pretreat-
ment assessments, probably reflecting the improvement in lower
urinary tract symptoms as a result of prostate gland shrinkage.
Our current study is the only randomised trial in prostate cancer
to address the issue of radiation ‘safety margin’ after initial
hormone therapy. Two separate issues arise. Firstly, is it the
prehormone or posthormone prostate volume that should be used
to define the radiation clinical target volume. Secondly, what is the
appropriate margin to account for geometric uncertainties in
treatment planning and delivery as well as prostate movement. The
choice of a 1.0 or 1.5cm margin in this trial was designed to
address the former question but clearly the improvements in
treatment accuracy that have occurred as treatment verification
techniques have become more sophisticated using, for example,
electronic portal imaging (Mubata et al, 1998) could have
influenced our results. However, we found no evidence for a
detriment in PSA control using a 1.0cm margin to the
posthormone treatment target volume. Despite the necessarily
wide confidence limits on this result from a small study, we could
not justify continuing to use a 1.5cm margin, as this larger
treatment volume was clearly related to an increase in radiation-
related side effects. This information was considered by the MRC
RT01 Data Monitoring Committee and it was agreed that Trial
Centres should be advised to use the smaller 1.0cm margin (in the
RT01 trial, the margin randomisation was omitted and margins of
1.0–1.5cm were chosen by the treating clinician). Several groups
are developing models based on dose volume histograms to predict
the likelihood of complications (Lu et al, 1995; Boersma et al, 1998;
Fiorino et al, 2003; Jackson et al, 2001; Wachter et al, 2001). This
study will add a very useful further patient data set to complement
our previous studies (Fenwick et al, 2001), which will be combined
with further information from the MRC RT01 trial. It is already
clear, however, that careful attempts to shield the rectum using
precise radiotherapy delivery methods can result in very low
toxicity profiles (Lee et al, 1996; Zelefsky et al, 1999). Increasing
standards of treatment verification and accuracy (Amer et al, 2001)
together with studies using marker seeds (Crook et al, 1995; Wu
et al, 2001) or dynamic magnetic resonance imaging (Padhani et al,
1999) have clarified the extent of prostate movement. This is
dependent on rectal distension and for patients with an empty
rectum on CT planning scans, more restricted posterior margins
may well be adequate and would lead to a further decrease in the
volume of the rectum treated with an expected further reduction in
treatment-related side effects.
In this trial, we used initial androgen suppression in conjunction
with conformal dose escalated radiotherapy as they are comple-
mentary treatment approaches in that both achieve improvement
in local treatment control and reduce radiation treatment volumes
(Dearnaley, 2001). Although androgen levels return to normal in
over 90% of men after short-course hormone therapy (Shahidi
et al, 2001), sexual dysfunction may be more common after
combined modality treatment. Future results from ongoing phase
III trials will help to define optimal contributions from high-dose
conformal radiation or combined modality treatments with the
aim of balancing the relative effectiveness and toxicities of these
different treatment approaches. Newer antiandrogens such as
Bicalutamide will need to be included in future treatment
strategies. For more advanced cancers, there is now good evidence
that prolonged courses of adjuvant hormonal therapy are of
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Figure 4 Cumulative grade X2 bowel and bladder toxicities by dose
and margin randomization. (A) Cumulative bowel toxicity grade X2b y
dose; (B) cumulative bladder toxicity grade X2 by dose; (C) cumulative
bowel toxicity grade X2 by margin; (D) cumulative bladder toxicity grade
X2 by margin.
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sadditional benefit (Roach III et al, 2000; Horwitz et al, 2001; Bolla
et al, 2002; Pilepich et al, 2003), but it is not yet known whether
dose escalation will produce further advantage.
The MRC RT01 trial completed recruitment of over 850 patients
in December 2001. The remaining ongoing dose escalation trials
(see above) give doses of 68–73Gy in the control groups and 78–
82Gy in the escalated dose groups. It is now a priority for the
radiotherapy community to deliver such treatments safely. A
further challenge has come from the hypothesis that the a–b ratio
for prostate cancer may be low, which implies that there would
be a therapeutic advantage from treating with large doses per
fraction in hypofractionated schedules (Duchesne and Peters,
1999; Brenner, 2000; King and Fowler, 2001). Such schedules, if
effective and safe, would be more convenient for patients and
make better use of sophisticated resources. Appropriate trials to
address these questions are currently under way in the UK and
elsewhere.
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